Zobrazeno 1 - 5
of 5
pro vyhledávání: ''
Autor:
Cindy Körner, Heike Wilhelm, Janine Jung, Angelika Wörner, Ewald Münstermann, Stefan Wiemann, Nese Erdem, Omar Salem
Publikováno v:
BMC Genomics
Background miRNAs are small noncoding RNA molecules that play an important role in post-transcriptional regulation of gene expression. Length and/or sequence variants of the same miRNA are termed isomiRs. While most isomiRs are functionally redundant
Autor:
Jhih Rong Lin, Zhengdong D. Zhang, Ying Cai, Cristina Montagna, Kelly O'Brien, Quanwei Zhang, Rubén Nogales-Cadenas, Wen Zhang
Publikováno v:
BMC Genomics
Background Malignant breast cancer with complex molecular mechanisms of progression and metastasis remains a leading cause of death in women. To improve diagnosis and drug development, it is critical to identify panels of genes and molecular pathways
Autor:
Andrew Tutt, Cheryl Gillett, Brian Burford, David Dornan, Anita Grigoriadis, Pierfrancesco Marra, Sarah E Pinder, Patrycja Gazinska, Lars Holmberg, Grazyna Fedorowicz, Anca Mera, Emanuele de Rinaldis, Zora Modrusan
Publikováno v:
BMC Genomics
BACKGROUND: This study focuses on the analysis of miRNAs expression data in a cohort of 181 well characterised breast cancer samples composed primarily of triple-negative (ER/PR/HER2-negative) tumours with associated genome-wide DNA and mRNA data, ex
Autor:
Francesca M. Buffa, David R. Mole, Ashwag Albukhari, Carme Camps, Syed Haider, Spyros Oikonomopoulos, Ioannis Ragousis, Peter J. Ratcliffe, Johannes Schödel, Hani Choudhry, Adrian L. Harris, Daniela Moralli
Publikováno v:
BMC Genomics
Transcriptional responses to hypoxia are central to the pathogenesis of many types of cancer. Today, pan-genome analyses of hypoxia have focused on protein-coding genes, however, the role of non-coding RNAs, in particular long non-coding RNAs (lncRNA
Autor:
Anita Grigoriadis, Jessica Frankum, Alan Mackay, Rachel Natrajan, Andrew Tutt, Pei Jun Wu, Elodie Noel, Jorge S. Reis-Filho
Publikováno v:
BMC Genomics
BMC Genomics, Vol 13, Iss 1, p 619 (2012)
BMC Genomics, Vol 13, Iss 1, p 619 (2012)
Background Triple-negative breast cancers (BC) represent a heterogeneous subtype of BCs, generally associated with an aggressive clinical course and where targeted therapies are currently limited. Target validation studies for all BC subtypes have la